致病性ATM变异携带者中对乳腺放疗耐受良好
该研究分析了71例携带ATM变异(15例为致病/可能致病,56例为意义不明变异)接受乳腺癌辅助放疗的患者,并与205例对照比较。结果显示,在调整患者及治疗相关因素后,急性及慢性毒副反应与无已知ATM突变者相似,且携带致病/可能致病ATM变异并接受保乳手术者的美容效果优良率高。
要点
- 携带致病/可能致病ATM变异的乳腺癌患者接受辅助放疗后,急性及慢性毒副反应与无已知ATM突变者无显著差异。
- 保乳术后接受放疗的致病/可能致病ATM变异携带者中,美容效果优良率高。
- 研究提示ATM变异携带者中乳腺放疗耐受良好,未观测到毒副反应增加。
核心结论
- 作为乳腺癌管理的一部分,放疗在致病/可能致病ATM变异携带者中耐受良好,毒副反应谱与无已知ATM突变的患者相似。
研究设计与样本
- 研究纳入71例接受乳腺癌辅助放疗的ATM变异携带者(15例为致病/可能致病,56例为意义不明变异),另纳入205例在同一时间段内连续治疗、经确认ATM野生型或未进行基因检测的患者作为对照。
- 回顾性审阅放疗计划,采用不良事件通用术语标准4.0版评估急性及慢性毒副反应。
- 采用Fisher精确检验比较组间毒副反应,采用Wilcoxon秩和检验评估患者特征差异。
主要发现
- 中位毒性随访时间为19.4个月,亚组中位随访时间分别为13.3个月(致病/可能致病组)、12.6个月(意义不明变异组)和23.3个月(对照组)。
- 放疗计划异质性、是否接受瘤床加量、乳腺/胸壁计划靶区大小方面无显著差异;对照组中低分次放疗的使用更多(P = .023)。
- 在考虑可能影响毒副反应的患者及治疗相关因素后,急性皮炎、色素沉着、湿性脱皮、乳腺/胸壁疼痛或乳腺水肿方面均无显著差异。
- 慢性乳腺/胸壁疼痛、硬结、毛细血管扩张或美容效果方面亦无显著差异。
- 在携带致病/可能致病ATM变异并接受保乳手术的患者中,观察到美容效果优良率高。
关键数值与推荐
- 急性及慢性毒副反应采用不良事件通用术语标准4.0版评估。
- 组间比较采用Fisher精确检验,患者特征差异采用Wilcoxon秩和检验。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There are mixed and limited data regarding radiation therapy (RT) tolerance in carriers of a germline pathogenic or likely pathogenic (P/LP) ATM variant. We investigated RT-related toxic effects in carriers of an ATM variant who received treatment for breast cancer. METHODS AND MATERIALS: We identified 71 patients treated with adjuvant RT for breast cancer who were carriers of a variant in ATM: 15 were classified as P/LP and 56 classified as variants of unknown significance (VUS). We additionally identified 205 consecutively treated patients during a similar timeframe who were either confirmed ATM wild type or had no prior genetic testing. RT plans were reviewed. Acute and chronic toxic effects were evaluated using Common Terminology Criteria for Adverse Events version 4.0 criteria. Fisher's exact tests for count data were performed to compare toxic effects between the cohorts (P/LP vs VUS vs control). Wilcoxon rank-sum testing was performed to assess for differences in patient characteristics. RESULTS: The median toxicity follow-up was 19.4 months; median follow-up for the subcohorts was 13.3 months (P/LP), 12.6 months (VUS), and 23.3 months (control). There were no significant differences in radiation plan heterogeneity, receipt of a boost, or size of breast/chest wall planning target volume. There was greater use of hypofractionated RT in the control cohort (P = .023). After accounting for patient- and treatment-related factors that may affect toxic effects, we found no significant differences with respect to acute dermatitis, hyperpigmentation, moist desquamation, breast/chest wall pain, or breast edema. Additionally, we found no significant differences with respect to chronic breast/chest wall pain, induration, telangiectasia, or cosmetic outcome. CONCLUSIONS: RT as part of the management of breast cancer was well tolerated in carriers of a P/LP ATM variant, with toxic effect profiles that were similar to those seen in patients without known ATM mutations. High rates of excellent or good cosmesis were observed in carriers of a P/LP ATM variant who underwent breast conservation.
引用
- Zureick AH, Zakalik D, Quinn TJ, et al. Breast Irradiation Is Well Tolerated in Carriers of a Pathogenic ATM Variant. Pract Radiat Oncol. 2023. PMID: 37742832. doi:10.1016/j.prro.2023.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。